最新消息

本公司針對研發中之新適應症,已委託國內外CRO公司完成之實驗(至2021年底)

2021年底,本公司針對研發中之新適應症,委託國內外CRO公司完成之實驗:

  • Hypoglycemic activity in T2DM mouse model (2017/7/19)
  • Efficacy study on attaining normo-glycaemia in diabetic mice (2018/2/12)
  • ES135 reduces blood glucose by central administration in mice (2019/12/31)
  • Determination of FGF Acidic Concentration in Rat and Dog Plasma by ELISA Method (2020/3/19)
  • 14-Day Subcutaneous Toxicity Study of ES135b in Rats (2020/3/25)
  • 14-Day Subcutaneous Toxicity Study of ES135b in Dogs (2020/3/25)
  • ES135b safety pharmacology study on cynomolgus monkeys (2020/9/9)
  • Study the effect of ES135b on blood glucose levels in mice (2020/12)
  • An Extended Non-GLP Single-dose Toxicity Study in Beagle Dog Administered rhFGF1 (ES135b) by Intrathecal Injection (IT) for Two Weeks Observation Period (2021/10/26)
  • An Extended Non-GLP Single-dose Toxicity Study in Beagle Dog Administered rhFGF1 (ES135b) by Intracerebroventricular (ICV) Injection for Two Weeks Observation Period (2021/10/26)
  • Study the effect of ES135b on blood glucose levels in mice (2021/11)
  • An extended Non-GLP single-dose toxicity study in SD rat administered rhFGF1 (ES135b) by intracerebroventricular injection for two weeks observation period (2021/12/10)

2021年雅祥努力嘗試協助國內取得COVID-19疫苗,後因國內疫苗供應充裕,已停止此工作項目。